Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

203
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
203
Drug Therapy01:28

Drug Therapy

32
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
32
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

98
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
98
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis00:59

Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis

35
Noncompartmental analyses offer an alternative method for describing drug pharmacokinetics without relying on a specific compartmental model. In this approach, the drug's pharmacokinetics are assumed to be linear, with the terminal phase log-linear. This assumption allows for simplified analysis and interpretation of the drug's behavior in the body.
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
35
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

463
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
463
Statistical Software for Data Analysis and Clinical Trials01:12

Statistical Software for Data Analysis and Clinical Trials

456
Statistical software is pivotal in data analysis and clinical trials by providing tools to analyze data, draw conclusions, and make predictions. These software packages range from simple data management applications to complex analytical platforms, supporting various statistical tests, models, and simulation techniques. Their significance lies in their ability to handle vast amounts of data with precision and efficiency, enabling researchers to validate hypotheses, identify trends, and make...
456

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Attention and learning strategies reveal distinct dimensions of psychiatric diseases.

Research square·2026
Same author

Association of Fetal Gene Regulatory Gene Deletions With Poor Cognition in Schizophrenia and Community-Based Samples.

The American journal of psychiatry·2026
Same author

Exploring Group Differences in Attenuated Symptoms and Functioning Between Clinical High-Risk Individuals With and Without Posttraumatic Stress Disorder.

Early intervention in psychiatry·2026
Same author

Regional, functional and transcriptomic decoding of multidimensional brain structure alterations in obsessive-compulsive disorder.

Nature communications·2026
Same author

Can Crowdsourced Annotations Improve AI-based Congestion Scoring For Bedside Lung Ultrasound?

Medical image computing and computer-assisted intervention : MICCAI ... International Conference on Medical Image Computing and Computer-Assisted Intervention·2026
Same author

QuNex recipes: Executable, human-readable workflows for reproducible neuroimaging research.

Imaging neuroscience (Cambridge, Mass.)·2026

Related Experiment Video

Updated: May 16, 2025

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

9.2K

Data analysis strategies for the Accelerating Medicines Partnership® Schizophrenia Program.

Nora Penzel1,2, Pablo Polosecki3, Jean Addington4

  • 1Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.

Schizophrenia (Heidelberg, Germany)
|April 3, 2025
PubMed
Summary
This summary is machine-generated.

The Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ) project uses baseline data and biomarkers to predict psychosis transition, remission, or persistence in individuals at clinical high-risk (CHR). Longitudinal data further identifies distinct clinical trajectories for CHR subgroups.

More Related Videos

Diagonal Method to Measure Synergy Among Any Number of Drugs
12:08

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

18.4K
Development of a Virtual Reality Assessment of Everyday Living Skills
10:32

Development of a Virtual Reality Assessment of Everyday Living Skills

Published on: April 23, 2014

18.3K

Related Experiment Videos

Last Updated: May 16, 2025

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

9.2K
Diagonal Method to Measure Synergy Among Any Number of Drugs
12:08

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

18.4K
Development of a Virtual Reality Assessment of Everyday Living Skills
10:32

Development of a Virtual Reality Assessment of Everyday Living Skills

Published on: April 23, 2014

18.3K

Area of Science:

  • Psychiatry and Neuroscience
  • Biomarker Discovery
  • Clinical High-Risk Studies

Background:

  • The Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ) project involves a large, international cohort at clinical high-risk for psychosis (CHR).
  • Previous studies in CHR populations have provided valuable insights but faced analytical challenges.
  • A robust data analysis strategy is crucial for maximizing the utility of the extensive AMP® SCZ dataset.

Purpose of the Study:

  • To outline the data analysis principles for the AMP® SCZ project.
  • To predict clinical outcomes (transition to psychosis, remission, persistence) in CHR individuals using baseline data and multimodal biomarkers.
  • To identify distinct clinical trajectories among CHR individuals using longitudinal data.

Main Methods:

  • Utilizing baseline clinical assessments and multimodal biomarkers to predict one- and two-year clinical endpoints.
  • Employing longitudinal clinical assessments and multimodal biomarkers to identify subgroup trajectories.
  • Leveraging legacy data from previous CHR studies to inform analysis pipeline design, benchmark experiments, and decision-making.
  • Developing mitigation strategies for anticipated analytical challenges.

Main Results:

  • The primary analysis aims to predict clinical endpoints in CHR individuals.
  • The secondary analysis focuses on identifying longitudinal trajectories differentiating CHR subgroups.
  • Legacy data analysis has informed the design of the AMP® SCZ analysis plan, addressing challenges from prior research.

Conclusions:

  • The AMP® SCZ project's analysis plan is designed to rigorously predict psychosis risk and identify patient subgroups.
  • The integration of baseline and longitudinal multimodal data, guided by legacy data insights, is key to advancing understanding of CHR.
  • This strategic approach aims to overcome previous analytical hurdles and enhance the predictive power of biomarkers and clinical assessments.